Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recruiting
N/A
Interventional Study
Transthyretin Amyloidosis
Heart Failure
Heart Failure, Diastolic
Amyloidosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 65 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 515 (estimated)
- Sponsor
- Massachusetts General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with a confirmed diagnosis of HFpEF.
* Age ≥65 years old
Exclusion Criteria:
* End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
* no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompens…
Contacts